目的 探討金水寶片聯合異丙托溴銨治療慢性支氣管炎的臨床療效。方法 選取2021年1月—2023年11月內蒙古醫(yī)科大學附屬醫(yī)院收治的慢性支氣管炎患者106例，隨機分為對照組（53例）和治療組（53例）。對照組霧化吸入吸入用異丙托溴銨溶液，2 mL/次，2次/d。在此基礎上，治療組口服金水寶片，4片/次，3次/d。兩組患者治療3個月。觀察兩組患者臨床療效，比較治療前后兩組患者主癥消失時間，肺功能指標用力肺活量（FVC）、呼氣峰值流量（PEF）和最大呼氣中段流量（MMEF）水平，外周血T淋巴細胞亞群水平，及血清嗜酸性粒細胞趨化因子（Eotaxin）、腫瘤壞死因子-α（TNF-α）、轉化生長因子-β1（TGF-β1）和內皮素-1（ET-1）水平。結果 治療后，治療組臨床總有效率為96.23%，明顯高于對照組的84.91%（P＜0.05）。治療后，治療組各項主癥的消失時間均明顯短于對照組（P＜0.05）。治療后，兩組患者FVC、PEF、MMEF、CD3^＋、CD4^＋和CD4^＋/CD8^＋水平明顯高于治療前，而CD8^＋、Eotaxin、TNF-α、TGF-β1和ET-1水平顯著低于治療前（P＜0.05），且治療后治療組患者肺功能指標、外周血T淋巴細胞亞群水平和血清因子水平明顯好于對照組（P＜0.05）。結論 金水寶片聯合異丙托溴銨治療慢性支氣管炎可加速患者癥狀緩解，提高肺功能及臨床療效，改善免疫功能及炎癥狀態(tài)。

Objective To explore the clinical efficacy of Jinshuibao Tablets combined with and ipratropium bromide in treatment of chronic bronchitis. Methods Patients (106 cases) with chronic bronchitis in the Affiliated Hospital of Inner Mongolia Medical University from January 2021 to November 2023 were randomly divided into control (53 cases) and treatment (53 cases) group. Patients in the control group were atomization inhalation administered with Ipratropium Bromide Solution for Inhalation, 2 mL/time, twice daily. Patients in the treatment group were po administered with Jinshuibao Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluations were evaluated, the disappearance time of main symptoms, lung function indicators FVC, PEF and MMEF, T lymphocyte subsets levels of peripheral blood, and the levels of serum Eotaxin, TNF-α, TGF-β1 and ET-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.23%, which was significantly higher than that of the control group (84.91%, P < 0.05). After treatment, the disappearance time of the main symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of FVC, PEF, MMEF, CD3^＋, CD4^＋ and CD4^＋/CD8^＋ in two groups were significantly higher than those before treatment, while the levels of CD8^＋, Eotaxin, TNF-α, TGF-β1 and ET-1 were significantly lower than those before treatment (P < 0.05), and the pulmonary function indexes, peripheral blood T lymphocyte subsets and serum factor levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Jinshuibao Tablets combined with ipratropium bromide in treatment of chronic bronchitis can accelerate the relief of symptoms, improve lung function and clinical efficacy and immune function and inflammatory state.

R974

內蒙古醫(yī)科大學面上項目（YKD2021MS017）